key: cord-1027817-hi93j22s
authors: Brown, Stav; Brown, Tal; Cederna, Paul S.; Rohrich, Rod J.
title: The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions
date: 2020-09-28
journal: Plast Reconstr Surg Glob Open
DOI: 10.1097/gox.0000000000003206
sha: a183d34cde42476bed48135a9923c08d419a2cdc
doc_id: 1027817
cord_uid: hi93j22s

The Coronavirus Disease 2019 (COVID-19) pandemic has presented a major threat to public health worldwide alongside unprecedented global economic and social implications. In the absence of a “gold standard” treatment, the rapid development of a safe and effective vaccine is considered the most promising way to control the pandemic. In recent years, traditional vaccine technologies have seemed insufficient to provide global protection against the rapid spread of emerging pandemics. Therefore, the establishment of novel approaches that are independent of whole pathogen cultivation, cost-effective, and able to be rapidly developed and produced on a large scale are of paramount importance for global health. This article summarizes the current efforts to develop a COVID-19 vaccine, including the ongoing and future anticipated clinical trials. We also provide plastic and reconstructive surgeons with insight into the novel technologies currently utilized for COVID-19 vaccine development, focusing on the very promising viral-vector-based and gene-based vaccine technologies. Each platform has its own advantages and disadvantages related to its efficacy and ability to induce certain immune responses, manufacturing capacity, and safety for human use. Once the fundamental key challenges have been addressed for viral-vector-based and gene-based vaccines, these novel technologies may become helpful in winning the fight against COVID-19 and transforming the future of health care.

The Coronavirus Disease 2019 (COVID-19) pandemic has presented a major threat to public health worldwide alongside unprecedented global economic and social implications. Identified in Wuhan, Hubei Province, China, in December 2019, the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), 1 well as passive immunization with convalescent plasma. 19 However, no "gold standard" treatment or prophylactic medication has been approved for COVID-19. Optimizing supportive care for COVID-19 positive patients remains the mainstay of therapy, including oxygen, mechanical ventilation, and treatment of the sequelae and complications. 20 With multiple waves of illness anticipated, 21 and in the absence of approved treatments, the development of a safe and effective vaccine will be a game-changing step in the global fight against COVID-19 and is considered the most promising way to eradicate the virus. 22 This article summarizes the current efforts to develop a SARS-CoV-2 vaccine, including the ongoing and future anticipated clinical trials. We also provide plastic and reconstructive surgeons with insight into the novel technologies currently utilized for SARS-CoV-2 vaccine development, focusing on the very promising viral-vector-based and gene-based vaccine technologies (Fig. 1 ).

Since the development of the first vaccine by Dr. Edward Jenner more than 200 years ago, 23 vaccinations have made an enormous contribution to global health. 24 However, the development process for conventional vaccines takes more than 10 years 25 and requires 4 Phases, [26] [27] [28] as summarized in Figure 2 . Therefore, the lack of time remains a major barrier for safe and effective vaccine development in outbreak situations.

Immunization can be derived from either passive or active immunization. 29 Passive immunization occurs with the transfer or administration of already preformed antibodies, providing temporary immunity. 29 One investigational treatment being explored for COVID-19 is the use of convalescent plasma collected from previously infected individuals, which is administered via direct transfusion to COVID-19 patients, in an attempt to confer passive immunity. [30] [31] [32] [33] [34] Active immunization occurs with the exposure to an antigen and typically produces long-term immunity due to the immune system stimulation. 29 The immune system is divided into two main subsystems: the innate system, which provides an initial, non-specific response, with no memory induced, and the adaptive system, which provides a later, antigen-specific response and induces immunological memory. 35 When antigens are introduced into the bloodstream via infection or vaccination, they are captured and processed by Antigen Presenting Cells (APCs), which then display an antigen-derived peptide fragment on their surfaces. APCs then migrate to lymph nodes, and activate T helper cells through a process called "antigenic presentation." T helper cells stimulate both arms of the adaptive immunity: humoral (antibody-based) and cellular.

Humoral immunity is achieved via differentiation, proliferation, and maturation of B-lymphocytes into antibody-secreting plasma cells and memory lymphocytes of the same antigenic specificity, and cell-mediated immunity is achieved via activation of naive cytotoxic T cells to active, antigen-specific cells. 29 The stimulation of both the humoral and cell-mediated arms of the adaptive system by the production of effector cells (plasma B cells for humoral immunity and active cytotoxic T cells for cell-medicated immunity) and memory cells is required to ensure protection upon re-exposure to the same antigen. 35 Figure 3 illustrates the immune stimulation response in detail.

The main conventional vaccine technologies include inactivated vaccines (which utilize a killed pathogen), subunit/recombinant vaccines (which utilize specific pieces of the pathogen administered along with adjuvants), toxoid vaccines (pathogen-toxin-based), and live attenuated vaccines. 36 Each platform has its own advantages and disadvantages related to its efficacy, immunogenicity, and ability to induce certain immune responses, manufacturing capacity, and safety for human use, as summarized in Table 2 . [36] [37] [38] [39] [40] [41] [42] 

In recent years, traditional vaccine technologies that consist of working with a virulent pathogen during manufacturing seem insufficient to provide global protection against the spread of emerging pandemics. Therefore, the establishment of novel approaches that are independent of pathogen cultivation (a relatively lengthy and high-risk process), are cost-effective, and could be rapidly developed and produced on a large scale, are of paramount importance for global health. 41 Two promising novel platforms that have generated significant attention in recent years due to their potential use for a variety of applications include the viral-vectorbased and gene-based vaccine technologies. Their advantages over conventional approaches highlight the role of these platforms in the new era of vaccinology, as potential game-changers in epidemics and emerging diseases. 43 The strengths and weaknesses of these platforms are summarized in Table 2 and discussed below.

Viral vector vaccines use separate, genetically engineered, viruses to carry DNA of target antigens into human cells. The DNA contained in the viral vector encodes antigens that, once expressed in the infected human cells, elicit antigen-specific humoral and cell-mediated immune responses via antigen presentation (Fig. 3) . 44 A variety of viruses have been employed as viral vectors, 45 with Adenovirus (Ad) vectors being the most commonly utilized due to their various advantages. Ad vectors' advantages over other viral vectors include their ability to enter a broad range of target cells in humans, 46 deliver various target antigens and large DNA insertions, 47 and induce potent humoral and cellular responses. 48 However, utilizing an unrelated virus for delivery poses several challenges in terms of manufacturing, safety, and immunogenicity, as summarized in Table 2 .

Gene-based vaccine platforms consist of genetic sequences in the form of plasmid DNA 49 and mRNA. 50 Once injected intramuscularly (IM), the genetic sequence enters the myocytes 51 to achieve encoding of the desired antigen. 52 The endogenously synthesized antigens are then secreted from myocytes for cross presentation and consecutive stimulation of humoral and cellular responses, • Able to induce potent, antigen-specific cellular and humoral immune responses

• Strong innate immune response Production and manufacturing:

• High producibility-independent of whole pathogen cultivation

• High specificity and accuracy-can be engineered easily to accurately express any antigen of choice, specific targeting, and processing in the cell due to antigen delivery as genetic information • High versatility-allows large insertions in genome and therefore the development of a large variety of vaccines • High specificity-able to encode any antigen of choice • Production and Manufacturing:

• Relatively high production costs

• High versatility-able to produce different vaccines using the same established production process and facility.

• Safe, rapid, and scalable production-based on in vitro systems that are simple to monitor, production free of animal-derived products

• Small amounts of expressed protein required due to amplification by the immune system DNA 4 12 Experimental Safety:

• Favorable safety profile-whole pathogen cultivation not required, non-infectious Safety:

• Potential long-term persistence, risk of genomic integration, potentially leading to mutagenesis and oncogenesis.

• Potential generation of autoantibodies

• Potential adverse effects due to cytokines/co-stimulatory molecules expression used to enhance DNA immunogenicity Efficacy:

• Generation of potent humoral and cellular immune responses

Efficacy:

• Low immunogenicity in humans • High stability Production and Manufacturing:

• High specificity-able to encode any antigen of choice Production and Manufacturing:

• Requires additional methods to enhance DNA uptake, expression, and immunogenicity: delivery devices such as gene gun, needle, jet injection, and in vivo electroporation and molecular adjuvants • Safe, rapid and scalable production-based on in vitro systems that are simple to monitor, production free of animal-derived products as illustrated in Figure 3 . 53 The main advantages of the gene-based platform include the construction of antigens directly from the genetic sequence of the desired protein and a generic manufacturing process, which allows for efficient production of different vaccines using the same established processes and facilities, given the genetic sequence is available. 54 Unlike conventional vaccine technologies, which consist of a lengthy process of inactivating or attenuating a live pathogen or making a recombinant protein, making a gene-based vaccine is relatively rapid and potentially lowrisk, eliminating the need to work with a virulent pathogen during manufacturing. 38 In addition, plasmid DNA and mRNA vaccine constructs encode only the antigen of interest, avoiding other redundant, potentially detrimental proteins and the replication of infectious viral particles. 55 However, since their initial presentation in 1990, 56 there has never been a commercial vaccine utilizing genebased technologies approved for use. There have been many technical challenges to overcome to enable the promise of the gene-based platform, 57 including optimizing the delivery of these foreign nucleic acids into human cells 58, 59 and increasing the potency, stability, and expression of the encoded protein. 38, 55 These goals have been achieved by new formulations, including lipids, polymers, and novel delivery devices for improved intracellular delivery and stability, and strong molecular adjuvants for improved potency. 60, 61 DNA-based Vaccines consist of antigen-encoding plasmids. While allowing a relatively simple, safe, and time-saving production process, the DNA-based platform poses several challenges related to administration, safety, and immunogenicity, as summarized in Table 2 . Unlike DNA vaccines, mRNA-based vaccines translate directly into the cytoplasm, undergo natural degradation, 50 and cannot integrate into the host genome. 41 These advantages in terms of safety, efficacy, and manufacturing make the mRNA technology a promising avenue for a rapid response to the emerging COVID-19 pandemic, and are summarized, alongside the disadvantages, in Table 2 .

Finding the most suitable target site for SARS-COV-2 vaccine development is extremely important. The SARS-CoV-2 coronavirus belongs to the subfamily of Coronavirinae, with a genomic structure of (+) ss-RNA. 62 Hoffman et al. 63 described the SARS-CoV-2 cell entry and replication mechanisms in detail and Bouhaddou et al. 64 recently demonstrated the role of virus-containing filopodia induced in host cells by SARS-CoV-2 in viral replication. Cell entry of SARS-CoV-2 is orchestrated by the viral spike (S) proteins, which give the virus its characteristic corona-like morphology, via binding the host cellular receptors. 63, 65 Due to its pivotal role, a vaccine against S protein can prevent SARS-CoV-2's proliferation and spread. 66 As of August 14, 2020, there have been 29 vaccine candidates in clinical trials, as summarized in Table 3 and Figure 1 . In total, 13 trials are currently in Phase 1, 8 in joint Phase 1/2, 2 in Phase 2 and 6 in Phase 3. An estimated 138 vaccine candidates are currently in preclinical studies. 67 While 12 clinical trials are based on traditional techniques utilizing inactivated viruses (5 trials), [68] [69] [70] [71] [72] [73] and protein subunits (7 trials), 74-77 16 trials utilize novel platforms including the viral vector-based platform (6 trials), [78] [79] [80] [81] [82] [83] [84] and gene-based platform (10 trials: 6 mRNAbased, 4 DNA-based). [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] Current viral-vector-based and gene-based vaccines under development target the S protein of SARS-CoV-2. 86,88

Three viral-vector-based vaccines are currently under clinical trials ( Table 3 ). The Adenovirus Type 5 Vector (Ad5-nCoV) and ChAdOx1 nCoV-19 trials are the furthest along in development and will be discussed below.

Ad5-nCoV is a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the S protein of SARS-CoV-2. 95 Ad5 is a non-replicating vector of human origin, and one of the most widely used adenoviral vectors. 96 However, the widespread pre-existing immunity to Ad5 among the human population might hinder its immunogenicity and hamper its clinical use. 97 Phase 1 results have recently been published, 80, 95 demonstrating that the Ad5 vectored COVID-19 vaccine was tolerable and immunogenic at 28 days post-vaccination. Most adverse reactions were mild or moderate in severity, with the most common adverse reactions being fever, fatigue, headache, and muscle pain. No serious adverse events were noted within 28 days post-vaccination. Neutralizing antibodies increased significantly at day 14, and peaked 28 days post-vaccination, while specific T-cell response peaked at day 14 after one administration of the vaccine. However, in patients with pre-existing anti-Ad5 immunity, both the specific antibody response and T-cell response induced by vaccination were diminished. 95 The recently published Phase II results 81, 98 have confirmed Phase I results, demonstrating that the Ad5-vectored COVID-19 vaccine was safe, and induced significant immune responses in the majority of recipients after a single immunization. Phase III results are expected before the end of 2020.

Adenoviral vectors of non-human origin induce enhanced memory and more poly-functional CD8 + T cells compared with Ad5 and are less likely to be hampered by pre-existing immunity. 48 

Totally, 4 DNA-based and 5 mRNA-based vaccines are currently in clinical trials (see Table 3 ). The m-RNA-1273 trial is the furthest along in development and will be discussed below.

mRNA-1273 developed in collaboration with the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH) is considered one of the frontrunners in vaccine development. The mRNA-1273 vaccine consists of mRNA of the S protein synthesized in vitro, and coated with lipid nanoparticles for effective delivery.

Phase I results have recently been published, 86, 102 demonstrating that mRNA-1273 was generally safe and well tolerated, with 1 incidence of a grade 3 adverse event (erythema around the injection site), and 3 incidences of grade 3 systemic symptoms (including fever, muscle pain and headache) seen at the highest dose group, only following the 2nd dose. All adverse events have been transient and self-resolving. No grade 4 adverse events or serious adverse events have been reported. Phase II is currently ongoing, 85 and Phase III is expected to commence before the end of July 2020 in collaboration with the NIAID. Phase III results are expected before the end of 2020. 102

While the preliminary results of the discussed trials are encouraging, whether a vaccine generates the needed types of immune responses to result in protective efficacy is unknown and cannot be predicted by Phase I studies. There still remain significant questions and uncertainties as to clinical efficacy and effects of potential mutations on the vaccine's immunogenicity and long-term efficacy, safety, and potential benefit for specific target populations.

One of the main questions that arise is whether a COVID-19 vaccine would be able to provide immunity, when it is still uncertain whether previously infected patients are protected from reinfection. [103] [104] [105] [106] [107] Research in other coronavirus species has shown that immunity may not be long-lasting, with 2-3 years of protection estimated from work with SARS and MERS. 102, 108, 109 To date, there is no evidence for cases of SARS-CoV-2 reinfections, 103 and preliminary evidence in humans 110 and rhesus macaques 111 suggests that acquired immunity may protect from future reinfection, at least temporarily 104, [111] [112] [113] with most patients who recovered from COVID-19 producing sufficient amounts of neutralizing antibodies to protect against reinfection. A recently reported case series also indicated sufficient neutralizing antibody titers in convalescent plasma to neutralize SARS-CoV-2 in 5 COVID-19 patients, who all recovered after treatment. 114 While further research is needed to assess the benefits and risks of convalescent plasma therapy for people with COVID-19, 33,34 these preliminary findings provide hope for the development of an effective vaccine against SARS-CoV-2. 32 However, there have been few reports of postrecovery positive PCR tests performed in asymptomatic or mildly symptomatic patients, which could be explained as either false-negative results, prolonged viral clearance, and shedding or reinfection. 106, 107, [115] [116] [117] Further points that need to be addressed to better understand the immune responses to SARS-CoV-2 and the optimal vaccine profile and administration regimens include the lack of correlation between antibody titer rates and clinical improvement, the durability of neutralizing antibodies, and their correlation with durable immunity. 118, 119 The current gaps in knowledge highlight the importance of inducing potent humoral and cellular immune responses as potentially generated by viral-vectorbased and gene-based vaccines.

Potential mutations in the S protein may also affect the long-term efficacy of a vaccine. There has been direct evidence of functionally meaningful S protein mutations that appear to mediate a higher binding affinity when compared with previous SARS viruses. 120 Therefore, it is difficult to ensure that the current novel vaccines targeting SARS-CoV-2 protein S could be used for a long term. This highlights the importance of a cost-effective platform that is able to produce different vaccines rapidly and safely using existing production processes and already established manufacturing infrastructure. This is one of the main potential strengths of the gene-based technology over the conventional vaccine development platforms.

There have been previous reports of systemic reactions to mRNA, DNA, and viral-vectored vaccines, including adverse reactions identified in the Ad5-nCoV 95 and mRNA-1273 Phase 1 trials. 89 These outcomes have raised concerns about the safety of these novel platforms. As previously discussed, one of the main concerns of utilizing mRNA-based platforms is the potential toxicity of synthetically formulated mRNA due to its inherent inflammatory nature. 55 The use of DNA-based vaccines and viral-vector-based vaccines raises safety concerns due to their potential long-term persistence, 121,122 genome integration, 123,124 autoantibody generation, potential induction of anti-vector immunity, 124 and adverse effects due to co-stimulatory molecule expression. 125 These safety concerns cannot be fully investigated by pre-clinical studies because humans may respond differently than the animal models used in the pre-clinical safety testing. 126 Therefore, it is of vital importance to fully characterize the potential risks of these novel platforms and adjust dosing schemes accordingly. This holds true especially for mRNA-based vaccines, where repeated administration (boosting) is needed for generating the desired neutralizing antibody titer levels. 127 

A major question that requires further investigation is whether the elderly and immunocompromised populations, who experience higher clinical attack rates and a more severe clinical course, 128 would be able to mount a sufficiently robust antibody response to provide immunity in response to the vaccine. Most current trials are designed to include healthy elderly participants as part of advanced clinical phases; however, safety and potential efficacy should be established to include immunocompromised patients.

In conclusion, the rapid development of an effective and safe vaccine has become the most promising way to control the COVID-19 pandemic. Over 20 candidate vaccines are in clinical trials and over 100 are in preclinical trials, utilizing both conventional and novel technologies. The viral-vector-based and gene-based vaccine technologies are promising novel platforms that have generated significant attention in recent years due to their potential use for a variety of applications. Their various advantages over conventional approaches highlight their role in the new era of vaccinology as potential game-changers in epidemics and emerging diseases. Once the fundamental key challenges have been addressed for viral-vector-based and gene-based vaccines, these novel technologies may become helpful in winning the fight against COVID-19 and in transforming the future of health care.

In the words of Louis Pasteur: In the field of observation, chance favors only the prepared mind.

Tel Aviv University 35 Klatskin St, Tel Aviv 69978, Israel E-mail: brown.stav@gmail.com

A novel coronavirus outbreak of global health concern

COVID-19 Dashboard by The Center for Systems Science and Engineering

Asymptomatic transmission, the Achilles' heel of current strategies to control COVID-19

Public Health-Seattle and King County and CDC COVID-19 Investigation Team. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility

Surviving the COVID-19 pandemic: Surge capacity planning for nonemergent surgery

How will country-based mitigation measures influence the course of the COVID-19 epidemic?

The COVID-19 pandemic: changing lives and lessons learned

Virtually perfect? telemedicine for COVID-19

Telemedicine in the era of the COVID-19 pandemic: Implications in facial plastic surgery

Coronavirus disease 2019 state guidelines on elective surgery: considerations for plastic and reconstructive surgeons

A summary of recommendations for plastic surgeons during the coronavirus disease 2019 outbreak

Plastic surgeons in the time of a pandemic: thoughts from the front line

The early effects of COVID-19 on plastic surgery residency training: the University of Washington experience

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency

The impact of COVID-19 on clinical trials

COVID-19-the search for effective therapy

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

A trial of Lopinavir-Ritonavir in adults hospitalized with severe COVID-19

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Coronavirus disease 2019 treatment: a review of early and emerging options

Beware of the second wave of COVID-19

Rational vaccine design in the time of COVID-19

Jenner, on the vaccine inoculation

Designing tomorrow's vaccines

Risk in vaccine research and development quantified

Clinical Trial-Related Terms. Grants and Funding. National Institute of Health (NIH)

National Institute of Health (NIH)

Food and Drug Administration (FDA)

Principles of Vaccination

Passive antibody therapy in COVID-19

Vaccines, convalescent plasma, and monoclonal antibodies for COVID-19

A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Fundamentals of vaccine immunology

Vaccine Types

Enlisting the mRNA vaccine platform to combat parasitic infections. Vaccines (Basel)

Advances in mRNA vaccines for infectious diseases

Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases

Vaccination strategies to combat novel corona virus SARS-CoV-2

New vaccine technologies to combat outbreak situations

Developing COVID-19 vaccines at pandemic speed

Novel vaccine technologies for the 21st century

Viral vectors: from virology to transgene expression

Vector-based genetically modified vaccines: exploiting Jenner's legacy

Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine

Multivalent and multipathogen viral vector vaccines

Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8 + T cells induced by different adenovirus vectors

DNA vaccines: an historical perspective and view to the future

mRNA vaccines -a new era in vaccinology

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

An evidence based perspective on mRNA-SARS-CoV-2 vaccine development

mRNA vaccine delivery using lipid nanoparticles

Gene Vaccines

A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel)

Direct gene transfer into mouse muscle in vivo

mRNA-based therapeuticsdeveloping a new class of drugs

Single-cell mRNA transfection studies: delivery, kinetics and statistics by numbers

DNA vaccination: a direct line to the immune system

Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening

DNA vaccines: ready for prime time?

The genetic sequence, origin, and diagnosis of SARS-CoV-2

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

The global phosphorylation landscape of SARS-CoV-2 infection

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Draft Landscape of COVID-19 Candidate Vaccines

A Phase I/II Clinical Trial for Inactivated Novel Coronavirus (2019-CoV) Vaccine (Vero cells)

Doubleblind, Placebo Parallel-controlled Phase I/II Clinical Trial for Inactivated Novel Coronavirus Pneumonia vaccine (Vero cells). Registration number: ChiCTR2000031809

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV). ClinicalTrials.gov

Available at https://clinicaltrials. gov/ct2/show/NCT04471519?term=bharat&cond=covid-19&draw=2&rank=1

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine with/without Matrix-M Adjuvant

SCB-2019 as COVID-19 Vaccine

National Library of Medicine. Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine

Available at https://clinicaltrials.gov/ct2/show/NCT04453852?term=vaccine&cond=covid-19&draw=5

A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19

A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers

A Phase I Clinical Trial for Recombinant Novel Coronavirus (2019-COV) Vaccine (adenoviral vector). Registration number: ChiCTR2000030906

Double-blinded, Placebo-controlled Phase II Clinical Trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector). Registration number: ChiCTR2000031781

An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine against COVID-19

A phase III study to investigate a vaccine against COVID-19

A Study of Ad26.COV2.S in Adults (COVID-19)

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers. ClinicalTrials.gov Identifier: NCT04336410. Available at

Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults. ClinicalTrials.gov Identifier: NCT04368728. Available at

Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women. Imperial College London

A Phase I Clinical Trial to Evaluate the Safety, Tolerance and Preliminary Immunogenicity of Different Doses of a SARS-CoV-2 mRNA Vaccine in Population Aged 18-59 years and 60 years and above

Novel Corona Virus-2019-nCov Vaccine by Intradermal Route in Healthy Subjects

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Novel viral vectors in infectious diseases

Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Development of nonhuman adenoviruses as vaccine vectors

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase ½, single-blind, randomised controlled trial

COVID-19 Oxford Vaccine Trial. The Oxford Vaccine Centre COVID-19 Phase II/III Clinical Trial Explained

An mRNA vaccine against SARS-CoV-2-preliminary report

COVID-19 and postinfection immunity: limited evidence, many remaining questions

Will we see protection or reinfection in COVID-19?

COVID-19 reinfection: myth or truth? SN

Positive RT-PCR test results in patients recovered from COVID-19

New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient

Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance

Persistence of antibodies against Middle East respiratory syndrome coronavirus

Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound?

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Antibody responses to SARS-CoV-2 in patients with COVID-19

Interpreting a COVID-19 test result

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China

False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence

Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: persistence, sampling issues, or re-infection

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Virological assessment of hospitalized patients with COVID-2019

Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: an in silico analysis

Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle

The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response

Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation

Developments in viral vectorbased vaccines. Vaccines (Basel)

Modulation of the immune response to DNA vaccine by co-delivery of costimulatory molecules

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an openlabel, non-randomised, prospective, first-in-human phase 1 clinical trial

mRNA as novel technology for passive immunotherapy

COVID-19 in older people: a rapid clinical review